We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

71 hedge funds and large institutions have $26.9M invested in Galectin Therapeutics in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 26 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

154% more call options, than puts

Call options by funds: $648K | Put options by funds: $255K

0.17% less ownership

Funds ownership: 17.82% → 17.65% (-0.17%)

5% less funds holding

Funds holding: 75 → 71 (-4)

13% less capital invested

Capital invested by funds: $31.1M → $26.9M (-$4.18M)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

50% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 26

Holders
71
Holders Change
-4
Holders Change %
-5.33%
% of All Funds
1.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
13
Reduced
26
Closed
8
Calls
$648K
Puts
$255K
Net Calls
+$393K
Net Calls Change
+$224K

Top Buyers

Rank Fund Capital Flow
1
Russell Investments Group
Russell Investments Group
United Kingdom
+$297K
2
Two Sigma Investments
Two Sigma Investments
New York
+$127K
3
TRCT
Tower Research Capital (TRC)
New York
+$96.1K
4
Osaic Holdings
Osaic Holdings
Arizona
+$65.5K
5
WAM
Wealthspire Advisors (Maryland)
Maryland
+$38.8K

Top Sellers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$241K
2
Morgan Stanley
Morgan Stanley
New York
-$94.1K
3
IWM
IHT Wealth Management
Illinois
-$86K
4
Northern Trust
Northern Trust
Illinois
-$79.5K
5
Ameriprise
Ameriprise
Minnesota
-$62K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$72K -$17.7K -6,337 -23%
Manulife (Manufacturers Life Insurance)
27
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$72K +$14.3K +5,093 +23%
RhumbLine Advisers
28
RhumbLine Advisers
Massachusetts
$68K -$17.8K -6,365 -20%
New York State Common Retirement Fund
29
New York State Common Retirement Fund
New York
$65K – – –
California Public Employees Retirement System
30
California Public Employees Retirement System
California
$63K – – –
AIG
31
American International Group
New York
$59K -$1.41K -505 -2%
Goldman Sachs
32
Goldman Sachs
New York
$55K -$392 -140 -0.7%
Deutsche Bank
33
Deutsche Bank
Germany
$54K +$5.03K +1,796 +10%
LPL Financial
34
LPL Financial
California
$50K -$27K -9,649 -34%
WS
35
Wedbush Securities
California
$47K -$8.4K -3,000 -15%
Barclays
36
Barclays
United Kingdom
$46K -$10.6K -3,771 -18%
CAN
37
Cetera Advisor Networks
California
$43K -$1.27K -455 -3%
CF
38
Centaurus Financial
California
$42K – – –
VCM
39
Vivaldi Capital Management
Illinois
$42K – – –
Two Sigma Advisers
40
Two Sigma Advisers
New York
$42K +$11.5K +4,100 +35%
AllianceBernstein
41
AllianceBernstein
Tennessee
$37K -$5.32K -1,900 -12%
WANY
42
Wealthspire Advisors (New York)
New York
$37K – – –
WAM
43
Wealthspire Advisors (Maryland)
Maryland
$37K +$38.8K +13,855 New
VOYA Investment Management
44
VOYA Investment Management
Georgia
$36K – – –
PPA
45
Parametric Portfolio Associates
Washington
$35K +$157 +56 +0.4%
BCM
46
Brookstone Capital Management
Illinois
$34K +$35.6K +12,710 New
AIC
47
Ameritas Investment Company
Nebraska
$33K – – –
SKK
48
Shepherd Kaplan Krochuk
Massachusetts
$32K – – –
William Blair & Company
49
William Blair & Company
Illinois
$29K – – –
DAS
50
Dynamic Advisor Solutions
Arizona
$27K – – –
1
2
3 4

GALT Hedge Fund Activity: Q3 2020 in Review

71 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2020, worth a combined $26.9M — down 13% from $31.1M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of GALT and 4 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 13 added.

The largest buyer was Russell Investments Group, opening a new position worth an estimated $297K. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $241K sold.

  • 71 institutional investors held Galectin Therapeutics (GALT) as of Q3 2020, down from 75 in Q2 2020.
  • Funds reported $26.9M of Galectin Therapeutics stock for Q3 2020, down 13% quarter-over-quarter.
  • 4 funds opened new Galectin Therapeutics positions in Q3 2020 and 8 closed out, a net change of -4 holders.
  • The largest Galectin Therapeutics buyer in Q3 2020 was Russell Investments Group, an estimated $297K added.
  • The largest Galectin Therapeutics seller in Q3 2020 was D.E. Shaw & Co, an estimated $241K sold.

Based on aggregated 13F filings for Q3 2020.